Citations

Showing 10 of 108162 citations.

Post Procedural Peak Left Atrial Contraction Strain Predicts Recurrence of Arrhythmia After Catheter Ablation of Atrial Fibrillation
Wen, Songnan , Indrabhinduwat, Manasawee, Brady, Peter A. , Miller, Fletcher A., Ammash, Naser M., Padang, Ratnasari , Lin, Grace , Pislaru, Cristina , Nkomo, Vuyisile T. , Pislaru, Sorin V.

Mayo Clinic

No container title available | February 17, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-199297/v1 Get It

Abstract Background: Left atrial (LA) function can be impaired by the atrial fibrillation (AF) ablation and might be associated with the risk of recurrence. We sought to determine whether the post-procedural changes in LA function impact the risk of recurrence following AF ablation. Methods: We retrospectively reviewed patients who underwent AF ablation between 2009 and 2011 and underwent transthoracic echocardiography before ablation, 1-day and 3-month after ablation. Peak left atrial contraction strain (PACS) and left atrial emptying fraction (LAEF) were evaluated during sinus rhythm and compared across the three time points. The primary endpoint was atrial tachyarrhythmia recurrence after ablation. Results: Out of 144 patients were enrolled (mean age 61±11 years, 77% male, 46% persistent AF). PACS and LAEF initially decreased 1-day following ablation but partially recovered within 3 months in PAF patients, with a similar trend in the PerAF patients. After median 24 months follow-up, 68 (47%) patients had recurrence. Patients with recurrence had higher PACS1-day than that in non-recurrence subjects (-10.9±5.0%%vs. -13.4±4.7, p=0.003). PACS1-day -12% distinguished recurrence cases with a sensitivity of 67.7% and specificity of 60.5%. The Kaplan-Meier curves showed significant difference in 5-year cumulative probability of recurrence between those with PACS≥ -12 % and PACS < -12% (log rank p<0.0001). Multivariate regression showed that PACS1-day was an independent risk factor of arrhythmia recurrence. Conclusions: Left atrial function deteriorates immediately following AF ablation and partially recovers in 3 months but remains abnormal in the majority of patients. PACS1-day post procedure predicts arrhythmia recurrence at long-term follow-up.
Cell Surface Glycoprotein CD24 Marks Bone Marrow-Derived Human Mesenchymal Stem/Stromal Cells with Reduced Proliferative and Differentiation Capacity In Vitro
Peppel, Jeroen van de , Schaaf, Gerben , Matos, Adriana Arruda , Guo, Yuan , Strini, Tanja, Verschoor, W., Dudakovic, Amel , Wijnen, André J. van , Leeuwen, Johannes P.T.M. van , van Wijnen, Andre J

Mayo Clinic

Stem Cells and Development | February 17, 2021 | Volume: 30 | Issue: 6 | Pages: 325-336

10.1089/scd.2021.0027 | PMID 33593128 Get It

Assessing Patient Symptoms Due to Nasal Septal Perforation: Development and Validation of the NOSE‐Perf Scale
Bansberg, Stephen F. , Marino, Michael J. , Taylor, Cullen M.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | February 17, 2021 | Volume: 165 | Issue: 5 | Pages: 739-744

10.1177/0194599821992010 | PMID 33588619 Get It

ObjectiveReporting patient symptoms due to nasal septal perforation (NSP) has been hindered by the lack of a validated disease‐specific symptom score. The purpose of this study was to develop and validate an instrument for assessing patient‐reported symptoms related to NSP.Study DesignValidation study.SettingA tertiary care center.MethodsThe Nasal Obstruction Symptom Evaluation (NOSE) scale was used as an initial construct to which 7 nonobstruction questions were added to measure septal perforation symptoms. The proposed NOSE‐Perf instrument was distributed to consecutive patients evaluated for NSP, those with nasal obstruction without NSP, and a control group without rhinologic complaints. Questionnaires were redistributed to the subgroup with NSP prior to treatment of the perforation.ResultsThe study instrument was completed by 31 patients with NSP, 17 with only nasal obstruction, and 22 without rhinologic complaint. Internal consistency was high throughout the entire instrument (Cronbach α = 0.935; 95% CI, 0.905‐0.954). Test‐retest reliability was demonstrated by very strong correlation between questionnaires completed by the same patient at least 1 week apart (r = 0.898, P <. 001). Discriminant validity was confirmed via a receiver operating characteristic (P <. 001, area under the curve = 0.700). The NOSE‐Perf scale was able to distinguish among all 3 study groups (P <. 001) and between NSP and nasal obstruction (P =. 024). When used alone, the NOSE scale could not discriminate between NSP and nasal obstruction (P =. 545).ConclusionsThe NOSE‐Perf scale is a validated and reliable clinical assessment tool that can be applied to adult patients with NSP.
Sinus rhythm heart rate increase after atrial fibrillation ablation is associated with lower risk of arrhythmia recurrence
Killu, Ammar M. , Witt, Chance M. , Sugrue, Alan , Vaidya, Vaibhav R. , Monahan, Kristi H. , Lenz, Charles J., Yogeswaran, Vidhushei , Sun, Philip Y. , Hodge, David O. , Friedman, Paul A. , Packer, Douglas L. , Asirvatham, Samuel J. , Sugrue, Alan M, Vaidya, Vaibhav , Barnes, Stephanie, Friedman, Paul A , Asirvatham, Samuel J , Sun, Philip , Barnes, Stephanie

Mayo Clinic

Pacing and Clinical Electrophysiology | February 17, 2021 | Volume: 44 | Issue: 4 | Pages: 651-656

10.1111/pace.14197 | PMID 33592679 Get It

AbstractBackgroundPulmonary vein isolation (PVI) with autonomic modulation may be more successful than PVI alone for atrial fibrillation (AF) ablation and may be signaled by changes in sinus rhythm heart rate (HR) post ablation. We sought to determine if a change in sinus rhythm HR predicted AF recurrence post PVI.MethodsPatients who underwent AF ablation from 2000 to 2011 were included if sinus rhythm was noted on ECG within 90 days pre and 7 days post ablation. Basic ECG interval and HR changes were analyzed and outcomes determined.ResultsA total of 1152 patients were identified (74.3% male, mean age 57 ± 11 years). Mean AF duration was 5.2 ± 5.3 years. Paroxysmal AF was noted in 712 (61.8%) of the patients. Mean EF was 61% ± 6%. Sinus rhythm HR was 61 ± 11 pre‐ablation and 76 ± 13 bpm post‐ablation (27% ± 24% increase, p < .001). The ability of relative HR change post‐ablation to predict AF recurrence was borderline (hazard ratio 0.65 [0.41–1.01], p = .067). With patients separated into quartiles based on the relative HR change, the upper quartile with the largest relative increase in HR had a significantly lower rate of AF recurrence compared to the lowest quartile following multi variable modeling (p = .038). There were significant changes in PR (171 ± 28 to 167 ± 30 ms) and QTc (424 ± 25 to 434 ± 29 ms) intervals (both p < .001) but these were not predictive of outcome.ConclusionRelative changes in HR post AF ablation correlates with AF recurrence. Further prospective studies are needed to confirm this relationship.
Outcomes of cardiac resynchronization therapy in patients with chemotherapy‐induced cardiomyopathy
Ezzeddine, Fatima M. , Saliba, Antoine N. , Jain, Vaibhav , Villarraga, Hector R. , Herrmann, Joerg , Asirvatham, Samuel J. , Cha, Yong‐Mei , Saliba, Antoine N. , Asirvatham, Samuel J , Saliba, Antoine N , Saliba, Antoine N , Ezzeddine, Fatima

Mayo Clinic

Pacing and Clinical Electrophysiology | February 16, 2021 | Volume: 44 | Issue: 4 | Pages: 625-632

10.1111/pace.14196 | PMID 33592678 Get It

AbstractBackgroundSeveral chemotherapy agents are associated with the development of non‐ischemic cardiomyopathy (NIC). When chemotherapy‐induced cardiomyopathy (CHIC) is associated with left bundle branch block (LBBB) and a left ventricular ejection fraction (LVEF) 35% or lower, cardiac resynchronization therapy (CRT) is often utilized to improve cardiac function and relieve symptoms.ObjectiveTo determine the echocardiographic and clinical outcomes of CRT in patients with CHIC.MethodsThe study included 29 patients with CHIC (CHIC group) and 58 patients with other types of NIC (control group) who underwent CRT implantation between 2004 and 2017. The primary endpoints were changes in LVEF, left ventricular end‐systolic diameter (LVESD), and left ventricular end‐diastolic diameter (LVEDD) at 6–18 months after CRT. The secondary outcomes included changes in left ventricular global longitudinal strain (GLS), systolic strain rate (SRS), early diastolic strain rate (SRE), and overall survival.ResultsOut of 29 patients with CHIC, 62.1% received chemotherapy for lymphoma, 13.7% for breast cancer, and 24.1% for sarcoma. The agent implicated in 93.1% of the patients was an anthracycline. Half of the patients had LBBB. The mean baseline LVEF was 28% ± 8%. The mean baseline QRS duration was 146 ± 26 ms. Twenty‐eight patients had post‐CRT follow‐up data. CRT was associated with improvement in echocardiographic outcomes in the CHIC group and the control group. There was no difference in overall survival between the two groups (log‐rank p = .148).ConclusionCRT improves left ventricular function and reverses remodeling in patients with CHIC.
Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in Anaplastic Thyroid Cancer Cells
Xu, Qinqin , Mackay, Ryan P. , Xiao, Adam Y., Copland, John A. , Weinberger, Paul

Mayo Clinic

International Journal of Molecular Sciences | February 16, 2021 | Volume: 22 | Issue: 4 | Pages: 1961

10.3390/ijms22041961 | PMID 33669447 Get It

Anaplastic thyroid cancer (ATC) is one of the most lethal malignancies with a median survival time of about 4 months. Currently, there is no effective treatment, and the development of new therapies is an important and urgent issue for ATC patients. YM155 is a small molecule that was identified as the top candidate in a high-throughput screen of small molecule inhibitors performed against a panel of ATC cell lines by the National Cancer Institute. However, there were no follow-up studies investigating YM155 in ATC. Here, we determined the effects of YM155 on ATC and human primary benign thyroid cell (PBTC) survival with alamarBlue assay. Our data show that YM155 inhibited proliferation of ATC cell lines while sparing normal thyroid cells, suggesting a high therapeutic window. YM155-induced DNA damage was detected by measuring phosphorylation of γ-H2AX as a marker for DNA double-strand breaks. The formamidopyrimidine-DNA glycosylase (FPG)-modified alkaline comet assay in conjunction with reactive oxygen species (ROS) assay and glutathione (GSH)/glutathione (GSSG) assay suggests that YM155-mediated oxidative stress contributes to DNA damage. In addition, we provide evidence that YM155 causes cell cycle arrest in S phase and in the G2/M transition and causes apoptosis, as seen with flow cytometry. In this study, we show for the first time the multiple effects of YM155 in ATC cells, furthering a potential therapeutic approach for ATC.
Improving the delivery of palliative care through predictive modeling and healthcare informatics
Murphree, Dennis H. , Wilson, Patrick M. , Asai, Shusaku , Quest, Daniel, Lin, Yaxiong, Mukherjee, Piyush, Chhugani, Nirmal, Strand, Jacob J. , Demuth, Gabriel , Mead, David W., Wright, Brian, Harrison, Andrew M. , Soleimani, Jalal , Pickering, Brian W. , Storlie, Curtis B. , Asai, Shusaku W, Quest, Daniel J, Mead, David, Harrison, Andrew , Harrison, Andrew Marc , Wright, Brian, Herasevich, Vitaly

Mayo Clinic

Journal of the American Medical Informatics Association | February 16, 2021 | Volume: 28 | Issue: 6 | Pages: 1065-1073

10.1093/jamia/ocaa211 | PMID 33611523 Get It

Abstract Objective Access to palliative care (PC) is important for many patients with uncontrolled symptom burden from serious or complex illness. However, many patients who could benefit from PC do not receive it early enough or at all. We sought to address this problem by building a predictive model into a comprehensive clinical framework with the aims to (i) identify in-hospital patients likely to benefit from a PC consult, and (ii) intervene on such patients by contacting their care team. Materials and Methods Electronic health record data for 68 349 inpatient encounters in 2017 at a large hospital were used to train a model to predict the need for PC consult. This model was published as a web service, connected to institutional data pipelines, and consumed by a downstream display application monitored by the PC team. For those patients that the PC team deems appropriate, a team member then contacts the patient’s corresponding care team. Results Training performance AUC based on a 20% holdout validation set was 0.90. The most influential variables were previous palliative care, hospital unit, Albumin, Troponin, and metastatic cancer. The model has been successfully integrated into the clinical workflow making real-time predictions on hundreds of patients per day. The model had an “in-production” AUC of 0.91. A clinical trial is currently underway to assess the effect on clinical outcomes. Conclusions A machine learning model can effectively predict the need for an inpatient PC consult and has been successfully integrated into practice to refer new patients to PC.
Arrhythmias in Cardiac Sarcoidosis Bench to Bedside
Rosenfeld, Lynda E. , Chung, Mina K. , Harding, Clifford V. , Spagnolo, Paolo , Grünewald, Johan , Appelbaum, Jason, Sauer, William H. , Culver, Daniel A. , Joglar, José A. , Lin, Ben A. , Jellis, Christine , Dickfeld, Timm-Michael, Kwon, Deborah , Cremer, Paul , Bogun, Frank , Bock, Ashley, Mehta, Davendra, Leis, Paul, Siontis, Konstantinos C. , Kaufman, Elizabeth S. , Crawford, Thomas , Zimetbaum, Peter , Zishiri, Edwin , Ellenbogen, Kenneth A. , Quadri, Syed M. , Vincent, Logan , Kalbfleish, Steven, Murgatroyd, Francis , Birnie, David H. , Okada, David R. , Bhat, Pavan , Bellumkonda, Lavanya , Blankstein, Ron , Cheng, Richard K. , Estep, Jerry D. , Cremer, Paul C , Bellumkonda, Lavanya , Cheng, Richard , Ellenbogen, Kenneth A , Dickfeld, Timm-Michael L. , Miller, Edward J. , Kron, Jordana , Singh, Jagmeet P , Chrispin, Jonathan , Patton, Kristen K. , Callahan, Thomas D , Judson, Marc A. , Maulion, Christopher , Blankstein, Ron , Farr, Maryjane

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | February 16, 2021 | Volume: 14 | Issue: 2 | Pages: No page available

10.1161/circep.120.009203 | PMID 33591816 Get It

Cardiac sarcoidosis is a component of an often multiorgan granulomatous disease of still uncertain cause. It is being recognized with increasing frequency, mainly as the result of heightened awareness and new diagnostic tests, specifically cardiac magnetic resonance imaging and 18 F-fluorodeoxyglucose positron emission tomography scans. The purpose of this case-based review is to highlight the potentially life-saving importance of making the early diagnosis of cardiac sarcoidosis using these new tools and to provide a framework for the optimal care of patients with this disease. We will review disease mechanisms as currently understood, associated arrhythmias including conduction abnormalities, and atrial and ventricular tachyarrhythmias, guideline-directed diagnostic criteria, screening of patients with extracardiac sarcoidosis, and the use of pacemakers and defibrillators in this setting. Treatment options, including those related to heart failure, and those which may help clarify disease mechanisms are included.
Implications of Neuroendocrine Tumor and Diabetes Mellitus on Patient Outcomes and Care: a Matched case–control Study
Kusne, Yael , Kosiorek, Heidi , Buras, Matthew , Verona, Patricia M , Coppola, Kyle , Rone, Kelley , Cook, Curtiss B. , Karlin, Nina J. , Kusne, Yael N , Kosiorek, Heidi E , Buras, Matthew R , Coppola, Kyle E , Rone, Kelley A , Cook, Curtiss B

Mayo Clinic

Future Science OA | February 16, 2021 | Volume: 7 | Issue: 5 | Pages: No page available

10.2144/fsoa-2020-0190 | PMID 34046189 Get It

Agreement of bioelectrical resistance, reactance, and phase angle values from supine and standing bioimpedance analyzers
Dellinger, Jacob R., Johnson, Baylor A, Benavides, Marqui L. , Stratton, Matthew T. , Siedler, Madelin R. , Stratton, Matthew T , Harty, Patrick S , Siedler, Madelin , Tinsley, Grant M , Moore, M. Lane , Harty, Patrick S.

Mayo Clinic

Physiological Measurement | February 16, 2021 | Volume: 42 | Issue: 3 | Pages: 035003

10.1088/1361-6579/abe6fa | PMID 33592586 Get It

Abstract Objective . Bioimpedance devices are commonly used to assess health parameters and track changes in body composition. However, the cross-sectional agreement between different devices has not been conclusively established. Thus, the objective of this investigation was to examine the agreement between raw bioelectrical variables (resistance, reactance, and phase angle at the 50 kHz frequency) obtained from three bioimpedance analyzers. Approach . Healthy male ( n = 76, mean ± SD; 33.8 ± 14.5 years; 83.9 ± 15.1 kg; 179.4 ± 6.9 cm) and female ( n = 103, mean ± SD; 33.4 ± 15.9 years; 65.6 ± 12.1 kg; 164.9 ± 6.4 cm) participants completed assessments using three bioimpedance devices: supine bioimpedance spectroscopy (BIS), supine single-frequency bioelectrical impedance analysis (SFBIA), and standing multi-frequency bioelectrical impedance analysis (MFBIA). Differences in raw bioelectrical variables between the devices were quantified via one-way analysis of variance for the total sample and for each sex. Equivalence testing was used to determine equivalence between methods. Main results . Significant differences in all bioelectrical variables were observed between the three devices when examining the total sample and males only. The devices appeared to exhibit slightly better agreement when analyzing female participants only. Equivalence testing using the total sample as well as males and females separately revealed that resistance and phase angle were equivalent between the supine devices (BIS, SFBIA), but not with the standing analyzer (MFBIA). Significance . The present study demonstrated disagreement between different bioimpedance analyzers for quantifying raw bioelectrical variables, with the poorest agreement between devices that employed different body positions during testing. These results suggest that researchers and clinicians should employ device-specific reference values to classify participants based on raw bioelectrical variables, such as phase angle. If reference values are needed but are unavailable for a particular bioimpedance analyzer, the set of reference values produced using the most similar analyzer and reference population should be selected.